Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours

The Lancet Oncology

Volumn 11, Issue 9, 2010, Pages 871-879

  Beauchesne, Patrick ^a  

^a Nancy Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; DIAZIQUONE; ETOPOSIDE; FLOXURIDINE; LIPOSOMAL CYTARABINE; MAFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; RADIOISOTOPE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TENASCIN 81C6 ANTIBODY; THIOTEPA; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARACHNOIDITIS; BACTERIAL MENINGITIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CELL THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIPLOPIA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLIOMA; HUMAN; HYPERTENSION; LEUKEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MEDULLOBLASTOMA; METASTASIS POTENTIAL; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SURVIVAL TIME; SYMPTOM; UNSPECIFIED SIDE EFFECT; COMPLICATION; INTRASPINAL DRUG ADMINISTRATION; MENINGEAL CARCINOMATOSIS; MENINGITIS; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; HUMANS; INJECTIONS, SPINAL; MENINGEAL CARCINOMATOSIS; MENINGITIS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 77956188377     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70034-6     Document Type: Review

References (75)

1. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61:733-743.
2. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 9:225-229.
3. Chamberlain MC Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003, 52:324-329.
4. Wasserstrom WR, Glass JP, Posner JB Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759-772.
5. Pace A, Fabi A Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006, 60:194-200.
6. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733-739.
7. Mokri B Low cerebrospinal fluid pressure syndromes. Neurol Clin 2004, 22:55-74.
8. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75:2919-2931.
9. Chamberlain MC, Kormanik PA Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996, 46:1674-1677.
10. Mason WP, Yeh SD, DeAngelis LM 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998, 50:438-444.
11. Chamberlain MC, Johnston SK, Glantz MJ Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 2009, 66:74-78.
12. Chamberlain MC, Tsao-Wei D Neoplastic Meningitis-Related Encephalopathy: Prognostic Significance. J Neurooncol 2005, 72:185-189.
13. Central Nervous System Cancers, v.1.2010 National Comprehensive Cancer Network (NCCN), (accessed June 21, 2010). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
14. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparaison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993, 11:561-569.
15. Glantz MJ, Jaeckle KA, Chamberlain MD, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt®) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumours. Clin Cancer Res 1999, 5:3394-3402.
16. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastases in breast cancer: a randomised study. Eur J Cancer 2004, 40:2726-2733.
17. Bleyer WA, Poplack DG Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979, 6:207-213.
18. Glantz MJ, Fisher R, Chamberlain MC Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. Proc Am Soc Clin Oncol 2006, 24:65. (abstr).
19. Shapiro WR, Young DF, Mehta BM Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161-166.
20. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655-1662.
21. Gangji D, Reaman GH, Cohen SR, Bleyer WA, Poplack DG Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980, 303:19-21.
22. Kerr JZ, Berg S, Blaney SM Intrathecal chemotherapy. Crypt Rev Oncol Hematol 2001, 37:227-236.
23. Shapiro WR, Young DF, Metha BM, et al. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161-167.
24. Gutin PH, Levi JA, Wiernik PH, et al. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977, 61:885-887.
25. Gutin PH, Weiss HD, Wiernik PH, et al. Intrathecal N,N',N″-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant disease. Cancer 1976, 38:1471-1475.
26. Shapiro WR, Schmid M, Glantz M, et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for the treatment of neoplastic meningitis. Proc Am Soc Clin Oncol 2006, 24:1528.
27. Fulton DS, Levin VA, Gutin PH, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumours and systemic tumours. Cancer Chemother Pharmacol 1982, 8:285-291.
28. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110-3116.
29. Jaeckle KA, Batchelor T, O'Day JO, et al. An open label trial sustained-release cytarabine (DepoCyt™) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002, 57:231-239.
30. Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21:143-147.
31. Gammon DC, Bhatt MS, Tran L, et al. Intrathecal topotecan in adult patients with neoplastic meiningitis. Am J Health Syst Pharm 2006, 63:2083-2086.
32. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncol 2008, 10:208-215.
33. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23:1555-1563.
34. Slavc I, Schuller E, Czech T, et al. Intrathecal mafosfamide therapy for pediatric brain tumours with meningeal dissemination. J Neuro Oncol 1998, 38:213-218.
35. Slavc I, Schuller E, Falgen J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): experience in 26 children with disseminated malignant brain tumours. J Neurooncol 2003, 64:239-247.
36. Chamberlain MC, Tsao-Wei DD, Groshen S Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006, 106:2021-2027.
37. Nakagawa H, Yamada M, Fukushima M, et al. Intrathecal 5-fluoro-2-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol 1999, 43:247-256.
38. Nakagawa H, Yamada M, Maeda N, et al. Clinical trial of intrathecal administration of 5-fluoro-2-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neurooncol 1999, 45:175-183.
39. Nakagawa H, Miyahara E, Suzujki T, et al. Continuous intrathecal administratin of 5-fluoro-2-deoxyuridine for the treatment of neoplastic meningitis. Neurosurg 2005, 57:266-280.
40. Berg SL, Balis FM, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143-148.
41. Adamson PC, Balis FM, Arndt CA, et al. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial and pharmacokinetic study. Cancer Res 1991, 51:6079-6083.
42. Quinn JA, Glantz M, Petros W, Rich, et al. Phase I trial of intrathecal Spartaject busulfan for patients with neoplastic meningitis. Proc Am Soc Clin Oncol 2002, 21:80. (abstr).
43. Gururangan S, Petros WP, Poussaint TY, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a pediatric brain tumor consortium study (PBTC-004). Clin Cancer Res 2006, 12:1540-1546.
44. Rueda Dominguez A, Olmos Hidalgo D, Viciana Garrido R, et al. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol 2005, 7:232-238.
45. Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003, 97:3053-3060.
46. Jonsson E, Fridborg H, Csoka K, et al. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human cells from patients. Br J Cancer 1997, 76:211-216.
47. Van der Gaast, Sonneveld P, Mans DR, et al. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol 1992, 29:335-337.
48. Fleischhack G, Reif S, Hasan C, et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 2001, 84:1453-1459.
49. Yamada M, Nakagawa H, Fukushima M, et al. In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neurooncol 1998, 37:115-121.
50. Zimm S, Collins J, Curt G, et al. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 1984, 44:1698-1701.
51. Archer GE, Sampson JH, McLendon RE, et al. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J Neurooncol 1999, 44:233-241.
52. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphoma: targeting the leptomeningeal compartment. Blood 2003, 101:466-468.
53. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350-1356.
54. Chamberlain MC, Johnston SK, Van Horn A, et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009, 91:271-277.
55. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006, 15:1373-1377.
56. Platini C, Long J, Walter S Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006, 7:778-780.
57. Ferrario C, Davidson A, Bouganim N, et al. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009, 20:792-795.
58. Colozza M, Minenza E, Gori S, et al. Extended survival of a HER2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemther Pharmacol 2009, 63:1157-1159.
59. Melisko ME, Glantz M, Rugo HS New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 2009, 6:25-33.
60. Mir O, Ropert S, Alexandre J, et al. High dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER2 overexpressing breast cancer. Ann Oncol 2008, 19:1978-1980.
61. Stemmler HJ, Mengle K, Schmitt M, et al. Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008, 19:832-836.
62. Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen R Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. Proc Am Soc Clin Oncol 2009, 27:103. (abstr).
63. 131I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 1988, 38:225-232.
64. 131I-radiolabelled monoclonal antibodies anti-tenascin 81C6 and antichondroitin proteglycan sulphate Mel-14F (ab')- a preliminary report. J Neurooncol 1995, 24:109-122.
65. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996, 2:963-972.
66. Chamberlain MC A phase II trial of intra-cerebrospinal fluid alpha-interferon in the treatment of neoplastic meningitis. Cancer 2002, 94:2675-2680.
67. Hankenson R, Hankenson A, Williams RM Intrathecal interferon alpha2b in meningeal carcinomatosis. Proc Am Soc Clin Oncol 1993, 12:179. (abstr).
68. Jaeckle K, Lukes S, Krown S, et al. Phase I study of intraventricularly administered human interferon in patients with leptomeningeal tumor. Ann Neurol 1983, 14:138-139.
69. Herrlinger U, Weller M, Schabet M New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998, 38:233-239.
70. Moser RP, Bruner JM, Grimm EA Biologic therapy for brain tumours. Cancer Bull 1991, 43:117-126.
71. Papadopoulos NE, Moser RP, Grimm EA, et al. Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma. Proc Am Soc Clin Oncol 1995, 14:1307.
72. Allen J, Hayes R, DaRosso R, et al. Intraventricular interleukin-2 (IL-2)/lymphokine activated killer (LAK) cells for leptomeningeal metastases (LM) in pediatric brain tumours. Proc Am Soc Clin Oncol 1993, 12:528.
73. Shimizu K, Okamoto Y, Miyao Y, et al. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 1987, 66:519-521.
74. Silvani A, Salmaggi A, Parmiani G, et al. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebro fluid: case report. Neurosurg 1994, 34:1078-1081.
75. Okamoto Y, Shimizu K, Tamura K, et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 1988, 94:47-52.